Drug Profile
IMO 2055
Alternative Names: EMD 1201081; HYB-2055; IMO-2055; IMOxine; TLR9 immunomodulatorLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen; Merck KGaA
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Colorectal cancer; Head and neck cancer; Non-small cell lung cancer
Highest Development Phases
- Suspended Colorectal cancer; Non-small cell lung cancer
- Discontinued Asthma; Cancer; Head and neck cancer; Renal cell carcinoma
Most Recent Events
- 17 Jan 2023 Idera Pharmaceuticals is now called Aceragen
- 15 Apr 2021 Discontinued - Phase-II for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in United Kingdom, United Kingdom, Slovakia, Poland, Hungary, France, Czech Republic, Belgium, USA (SC)
- 15 Apr 2021 Discontinued - Preclinical for Cancer in USA (Intratumoural)